Irish Blood Transfusion Service (IBTS)http://hdl.handle.net/10147/1903432024-03-27T04:09:11Z2024-03-27T04:09:11ZYou may need a blood transfusionNational Transfusion Advisory Group (NATG)http://hdl.handle.net/10147/6316842022-03-30T01:53:56Z2021-07-01T00:00:00ZYou may need a blood transfusion
National Transfusion Advisory Group (NATG)
This leaflet is designed to help you and your family understand what a
blood transfusion is and how you can help make this a safer treatment for
you.
Your doctor or nurse will explain if you are likely to need a blood transfusion
and why. They will ask your permission to give you a blood transfusion. This
means you share the decision to receive a blood transfusion. If you are
unconscious, your doctor must treat you in your best interest. This includes
giving you a transfusion without getting permission from you. (See Q9.)
2021-07-01T00:00:00ZA snapshot of ABO, RH, and JK blood group systems in modern Ireland.Browne, AnneKinsella, AnthonyKeogh, MoiraMorris, KieranField, Stephenhttp://hdl.handle.net/10147/6311052022-01-26T01:53:08Z2021-06-12T00:00:00ZA snapshot of ABO, RH, and JK blood group systems in modern Ireland.
Browne, Anne; Kinsella, Anthony; Keogh, Moira; Morris, Kieran; Field, Stephen
The number of donors tested was 3427. ABO phenotype: A: 29.82%, B: 12.02%, O: 54.95% and A,B: 3.21%. RHD: 82.26%. RHCE: R1R1: 17.62%, R2R2: 2.89%, R1R2: 13.95%, R1r: 33.35%, R2r: 13.07%, Ror: 1.25%, R1RZ: 0.06%, R2RZ: 0.06%, r'r: 0.55%, r″r: 0.53%, rr: 16.66%. Kidd phenotype: Jk(a + b+): 49.63%, Jk(a-b+): 23.34%, Jk(a + b-): 27.02%.
Objectives: This study aimed to capture a snapshot of the Irish population to determine if there had been any changes in the ABO and RH blood group system (BGS) distribution from previous Irish studies and to establish an Irish JK BGS frequency, providing real time donor information to the Irish Blood Transfusion Service (IBTS).
Background: Ireland's population is constantly increasing and becoming more diverse, this has potential implications for the IBTS to provide blood with extended phenotypes for certain cohorts of patients.
Materials and methods: All first time blood donors had relevant testing performed in the Automated Donor Grouping (ADG) laboratory using the Beckman Coulter PK7300 analyzer with appropriate antisera by validated methods. All pertinent information and test results were categorized and analyzed.
Results: The number of donors tested was 3427. ABO phenotype: A: 29.82%, B: 12.02%, O: 54.95% and A,B: 3.21%. RHD: 82.26%. RHCE: R1R1: 17.62%, R2R2: 2.89%, R1R2: 13.95%, R1r: 33.35%, R2r: 13.07%, Ror: 1.25%, R1RZ: 0.06%, R2RZ: 0.06%, r'r: 0.55%, r″r: 0.53%, rr: 16.66%. Kidd phenotype: Jk(a + b+): 49.63%, Jk(a-b+): 23.34%, Jk(a + b-): 27.02%.
Conclusion: The observed frequencies for the relevant BGSs remained relatively unchanged to the prevalence values expected; however, statistically significant differences between the 2015 study and some of the previous studies were found for ABO distribution. 14.24% of the first time donors were born outside Ireland and statistically significant differences (P-value < 0.001) were noted for aspects of the ABO and Rh phenotype distribution for the Irish born donors (BiI) vs those born outside Ireland (BoI).
2021-06-12T00:00:00ZIBTS Research & Development Strategy 2021 to 2023Irish Blood Transfusion Societyhttp://hdl.handle.net/10147/6306502021-10-23T01:44:02Z2021-04-01T00:00:00ZIBTS Research & Development Strategy 2021 to 2023
Irish Blood Transfusion Society
The Connections that Count strategy for
2021 to 2025 provides a framework for us
to deliver programmes of change, including
the implementation of a research and
development strategy which is built into the
pillar of Supporting Better Healthcare.
We are responsible for the national blood
supply for Ireland and therefore our
coordinated research activities must be
informed by emerging risks and opportunities
which ultimately optimise patient care and
help position us at the forefront of blood
transfusion medicine and science.
The rapidly evolving fields of transfusion,
transplantation and laboratory diagnostics
mean it is imperative that upcoming changes
to clinical practice, testing, production and
donation, are always considered and prepared
for. One of our core functions, as set out
in the IBTS Statutory Instrument is a remit
to ‘organise, provide, assist or encourage
research and the training and teaching
of persons in matters relating to blood
transfusion, transplantation and preparation
of blood products’.
It is, therefore, essential that a
comprehensive research and development
programme underpins our services to donors,
patients and hospitals.
This strategy was developed over the course of
5 months, during which regular consultations
with the Chief Executive Officer, Medical and
Scientific Director and senior research staff
were carried out. The complimentary expertise
of our scientific and clinical teams means
we already have a wealth of talent with the
capacity for progressing the proposed research
and development programme. This strategy
demonstrates our on-going commitment
to supporting research, and outlines the
necessary steps for the development
and implementation of a structured and
progressive research programme within our
organisation.
2021-04-01T00:00:00ZIrish Blood Transfusion Service Research & Development Strategy 2021 to 2023Irish Blood Transfusion Service (IBTS)http://hdl.handle.net/10147/6293042021-05-05T02:32:28Z2021-05-01T00:00:00ZIrish Blood Transfusion Service Research & Development Strategy 2021 to 2023
Irish Blood Transfusion Service (IBTS)
The rapidly evolving fields of transfusion,
transplantation and laboratory diagnostics
mean it is imperative that upcoming changes
to clinical practice, testing, production and
donation, are always considered and prepared
for. One of our core functions, as set out
in the IBTS Statutory Instrument is a remit
to ‘organise, provide, assist or encourage
research and the training and teaching
of persons in matters relating to blood
transfusion, transplantation and preparation
of blood products’.
It is, therefore, essential that a
comprehensive research and development
programme underpins our services to donors,
patients and hospitals.
This strategy was developed over the course of
5 months, during which regular consultations
with the Chief Executive Officer, Medical and
Scientific Director and senior research staff
were carried out. The complimentary expertise
of our scientific and clinical teams means
we already have a wealth of talent with the
capacity for progressing the proposed research
and development programme. This strategy
demonstrates our on-going commitment
to supporting research, and outlines the
necessary steps for the development
and implementation of a structured and
progressive research programme within our
organisation.
2021-05-01T00:00:00ZTransfusion-transmitted hepatitis B virus (HBV) infection from an individual-donation nucleic acid (ID-NAT) non-reactive donor.O'Flaherty, NUshiro-Lumb, IPomeroy, LIjaz, SBoland, FDe Gascun, CFitzgerald, JO'Riordan, Jhttp://hdl.handle.net/10147/6228062019-08-30T11:52:56Z2018-02-14T00:00:00ZTransfusion-transmitted hepatitis B virus (HBV) infection from an individual-donation nucleic acid (ID-NAT) non-reactive donor.
O'Flaherty, N; Ushiro-Lumb, I; Pomeroy, L; Ijaz, S; Boland, F; De Gascun, C; Fitzgerald, J; O'Riordan, J
Lookback was initiated upon notification of an acute HBV infection in a repeat Irish donor, 108 days post-donation. The donation screened non-reactive by individual-donation nucleic acid testing (ID-NAT) using the Procleix Ultrio Elite multiplex assay and again when the archived sample was retested, but the discriminatory assay for HBV was reactive. The immunocompromised recipient of the implicated red cell component was tested 110 days post-transfusion, revealing a HBV DNA viral load of 470 IU/ml. Genotype C2 sequences identical across two regions of the HBV genome were found in samples from the donor and recipient.
2018-02-14T00:00:00ZBlood Transfusion Service Board annual report 1999Blood Transfusion Service Board (BTSB)http://hdl.handle.net/10147/3441152019-08-30T11:57:44Z2000-01-01T00:00:00ZBlood Transfusion Service Board annual report 1999
Blood Transfusion Service Board (BTSB)
I was appointed to chair the Board of the BTSB in April 1999 and have been engaged on a very deep learning curve since then. The organisation is in the throes of enormous changes under the very able direction of the CEO and the National Medical Director. The BTSH has a dear mission to ensure the supply of blood and blood
products to Irish patients and to ensure that the quality and safety of products are at the highest international standards. The BTSB has a complex network of relationships in achieving this important mission. It
includes among its stakeholders its staff, the blood donors, the patients, their medical advisers, the Hospitals, the Department of Health and Children ,and the Irish Medicines Board. Patricia C. Barker Chairman.
2000-01-01T00:00:00ZBlood Transfusion Service Board annual report 1998Blood Transfusion Service Boardhttp://hdl.handle.net/10147/3372972019-08-30T13:00:58Z1998-01-01T00:00:00ZBlood Transfusion Service Board annual report 1998
Blood Transfusion Service Board
The year under review was another difficult
and challenging year for the Blood Transfusion
Service Board. It was also the year in which
many solid foundations were laid, which will
assist in redeveloping and refocusing blood
transfusion services in Ireland. In all thal is
taking place, it would be easy to overlook the
simple fact that blood saves lives. Every week
hundreds of patients in hospitals throughout
Ireland are helped in their recovery by the
ready availability of blood and blood products.
The Board and the recipients of blood are
indebted to the 100,000 donors who gave
160,000 units of blood during the year.
1998-01-01T00:00:00ZNational Haemovigilance Office report 2008 - 2009National Haemovigilance Officehttp://hdl.handle.net/10147/2982472019-08-30T12:56:24Z2011-08-01T00:00:00ZNational Haemovigilance Office report 2008 - 2009
National Haemovigilance Office
2011-08-01T00:00:00ZReport of the review panel on tesing of blood for transfusion: IrelandReview Panel on Testing of Blood for Transfusionhttp://hdl.handle.net/10147/2492322019-08-30T12:14:05Z2002-09-01T00:00:00ZReport of the review panel on tesing of blood for transfusion: Ireland
Review Panel on Testing of Blood for Transfusion
The Working Group: a panel of three international transfusion medicine specialists
(the Panel) was formed to review issues surrounding the controversy about where the
blood donated for transfusion in Ireland should be tested. The Panel met in Ireland in
late May and again in early July. Interested parties were interviewed in both Cork and
Dublin and the blood centres in each city were visited. Among those interviewed was
the Minister of Health and Children. Many documents were reviewed, including, but
not limited to, standard operating procedures (SOPs) at both centres, inspection and
news reports, and recommendations of several previous groups and individuals charged
to evaluate the Irish blood programme.
2002-09-01T00:00:00ZThe proposal to discontinue blood testing at the Munster Centre of the Irish Blood Transfusion Service Board (BTSB) - assessment by a representative regional groupIrish Blood Transfusion Service (IBTS)http://hdl.handle.net/10147/2479912019-08-30T12:14:24Z1998-01-01T00:00:00ZThe proposal to discontinue blood testing at the Munster Centre of the Irish Blood Transfusion Service Board (BTSB) - assessment by a representative regional group
Irish Blood Transfusion Service (IBTS)
The role of the Irish Blood Transfusion Service is crucial to the operation of our health care system. In its 1965 Establishment Order, the key functions of the BTSB are
described, inter alia, as follows
(a) to take over the property {including chosen-in-action}, assets, rights and
liabilities of the Company;
(b) to organise and administer a blood transfusion service (hereinafter referred to
as "the Service '') including the processing or supply of blood derivatives or
other blood products and also including blood group and other tests in relation
to specimens of blood received by the Board;
(e) to make available blood and blood products;
(d) to make available equipment or re-agents suitable for use in relation to the
service;
(e) to make such charges (if any) as the Board thinks fit,for the services referred
(f) to furnish advice, information and assistance in relation to any aspect of the
service to the Minister, any health authority or any hospital authority;
(g)to make any necessary provision for publicity in relation to the service;
(h) to organise, provide, assist or encourage research and the training and
teaching of persons in matters relating to blood transfusion and the
preparation of blood products, and
(i) to co-operate with other bodies with analogous scientific functions.
1998-01-01T00:00:00Z